This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge?
by Zacks Equity Research
PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.
PBH or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
PBH vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
by Moumi Mondal
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
Should Prestige Consumer Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
Investors remain optimistic about PBH stock due to its strong focus on brand building.
PBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
All You Need to Know About Prestige Consumer Healthcare (PBH) Rating Upgrade to Buy
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
by Zacks Equity Research
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
Prestige Consumer Healthcare (PBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Prestige Consumer Healthcare (PBH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 0% and 0.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Prestige Consumer Healthcare (PBH) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Prestige Consumer Healthcare (PBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
What Makes Prestige Consumer Healthcare (PBH) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Here's Why 'Trend' Investors Would Love Betting on Prestige Consumer Healthcare (PBH)
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink
by Zacks Equity Research
Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.
Prestige Consumer Healthcare (PBH) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 4.65% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Tops Q2 Earnings Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 42.86% and 12.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?